Biren Saraiya

Dr. Biren Saraiya

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
EPElizabeth Pan
Elizabeth Pan
WXWanling Xie
Wanling Xie
AAArchana Ajmera
Archana Ajmera
AAArlene Araneta
Arlene Araneta
CJCHRISTINA A.M. JAMIESON
CHRISTINA A.M. JAMIESON
RMRana R. McKay
Rana R. McKay
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought to demonstrate the safety and efficacy of olaparib + radium-223. We conducted a multicenter phase I 3+3 dose escalation study of olaparib with fixed dose radium-223 in patients with mCRPC with bone metastases. The primary objective was to establish the RP2D of olaparib, with secondary objectives of safety, PSA response, alkaline phosphatase response, radiographic progression-free survival (rPFS), overall survival, and efficacy by homologous recombination repair (HRR) gene status. Twelve patients were enrolled; all patients received a prior androgen receptor signaling inhibitor (ARSI; 100%) and 3 patients (25%) prior docetaxel. Dose-limiting toxicities (DLT) included cytopenias, fatigue, and nausea. No DLTs were seen in the observation period however delayed toxicities guided the RP2D. The RP2D of olaparib was 200 mg orally twice daily with radium-223. The most common treatment-related adverse events were fatigue (92%) and anemia (58%). The rPFS at 6 months was 58% (95% confidence interval, 27%–80%). Nine patients were evaluable for HRR gene status; 1 had a BRCA2 alteration (rPFS 11.8 months) and 1 had a CDK12 alteration (rPFS 3.1 months). Olaparib can be safely combined with radium-223 at the RP2D 200 mg orally twice daily with fixed dose radium-223. Early clinical benefit was observed and will be investigated in a phase II study.

9 February 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
MNMolly A. Nowels
Molly A. Nowels
SKSaurabh Kalra
Saurabh Kalra
PDPaul Duberstein
Paul Duberstein
ECEmily Coakley
Emily Coakley
BSBiren Saraiya
Biren Saraiya
EKElissa Kozlov
Elissa Kozlov

9 September 2021 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
LGLogin S. George
Login S. George
KMKonstantina Matsoukas
Konstantina Matsoukas
DMDaniel C. McFarland
Daniel C. McFarland
JBJennifer M. Bowers
Jennifer M. Bowers
MDMeredith J. Doherty
Meredith J. Doherty
WBWilliam Breitbart
William Breitbart

6 May 2019 in BMC Urology
Verified
Journal Article
Open access
PDF file
SKSinae Kim
Sinae Kim
ASArnav Srivastava
Arnav Srivastava
BSBiren Saraiya
Biren Saraiya
TMTina Mayer
Tina Mayer
WKWun-Jae Kim
Wun-Jae Kim
IKIsaac Kim
Isaac Kim
In this era of precision medicine, the DNA damage response (DDR) pathway has been shown to be a viable target of intervention in metastatic castration-resistant prostate cancer (CRPC) as approximately one-third of CRPC patients harbor DDR pathway mutations. To determine whether DDR pathway is a potential therapeutic target in localized disease, we analyzed The Cancer Genome Atlas (TCGA) in the present study. TCGA is a publically available cancer genome database that is sponsored by the United States National Cancer Institute. Total of 455 cases were available in the database at the time of this analysis. DDR pathway gene mutations or copy number alterations were present in 136 (29.9%) of the 455 cases. On a univariate analysis, DDR pathway status did not correlate with serum prostate specific antigen, tumor stage or grade. However, among patients with high-risk features post-operatively (pathologic stage ≥ T3, Gleason score ≥ 8, or PSA > 20 ng/ml), DDR pathway alteration was associated with a lower overall survival (p = 0.0291). Collectively these results suggest that DDR pathway alterations may also be significant in localized prostate cancer and agents such as PARP inhibitors should be considered in patients with a high-risk disease.

9 March 2022 in Prostate International
Verified
Journal Article
Open access
IKIsaac Kim
Isaac Kim
AMAntonina Mitrofanova
Antonina Mitrofanova
SPSukanya Panja
Sukanya Panja
JSJoshua Sterling
Joshua Sterling
ASArnav Srivastava
Arnav Srivastava
SHShigeo Horie
Shigeo Horie
Approximately 7% of patients with newly diagnosed prostate cancer (PCa) in the US will have have metastatic disease. The dogma that there is no role for surgery in this population has been questioned recently. Here we report long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. This is a multicenter phase 1 trial. The major inclusion criterion was biopsy proven N1M0 or NxM1a/b PCa. Primary end point was the Clavien-Dindo-based major complication rate. Secondary outcomes were biochemical progression and overall survival. RNA-seq correlative study was conducted in nine select cases as a pilot study. Final accrual was 32 patients of which 25 and 7 were cNxM1 and cN1M0, respectively. With the median follow-up of 46 months (interquartile range 31.7 - 52.7 months), 25 out of the 32 patients (75%) were alive at the time of last contact. There were three disparate groups based on the oncologic outcome: favorable, intermediate, and poor. In seven men with favorable response, androgen deprivation therapy was switched to intermittent approach and five remain free of any evidence of disease after more than two years off all systemic therapy with the normalization of serum testosterone. Of these five patients, three had M1 disease. Long-term use of one pad or less per day was 80%. RNA-seq analysis revealed an enriched downregulation of tumor necrosis factor (TNF)-α signature in the favorable group. Overall long-term oncologic outcome of cytoreductive radical prostatectomy was significantly higher than historical results. Importantly, the combination of surgery with systemic therapy may result in a long durable response in a minority of men who present with metastatic PCa.

4 May 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
IGIrina B. Grafova
Irina B. Grafova
SMSharon L. Manne
Sharon L. Manne
EBElisa V. Bandera
Elisa V. Bandera
BSBiren Saraiya
Biren Saraiya
ALAdana Llanos
Adana Llanos
PDPaul Duberstein
Paul Duberstein